GenoMed's WNV Treatment May Work for Avian Influenza
President Bush announced yesterday that the US has already purchased $100 million worth of a vaccine from Sanofi-Pasteur, a division of the European drug giant Sanofi-Aventis. Sanofi-Pasteur's vaccine is weak, requiring two doses of 90 micrograms to raise antibody titers. Good vaccines usually are effective at doses of only a few micrograms.
Secondly, the H5N1 type of avian influenza virus which served as the basis for Sanofi-Pasteur's vaccine cannot yet jump from person to person. The strain of virus which will cause the avian flu pandemic must be able to jump from person to person. It will be a mutated version of the H5N1 virus, whose composition cannot even be guessed at now. It is highly unlikely that Sanofi-Pasteur's weak vaccine will raise neutralizing antibodies against a mutant virus whose composition is as yet unknown.
Finally, the antiviral drugs stockpiled by the US, oseltamivir (Tamiflu, made by Roche) and zanimivir (Relenza, made by Glaxo-Smith-Kline), have mild activity against regular influenza but no proven activity against avian influenza in humans.
Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "President Bush's action, although timely, may be ill advised. For the past three years, both the CDC and the WHO have steadfastly ignored our novel anti-viral approach, which has achieved over 80% treatment success in West Nile virus encephalitis and which should be equally effective against avian influenza. If the WHO had put us in touch with clinicians in Southeast Asia treating avian influenza cases as we've asked for the past three winters, we'd already know by now."
Continued Dr. Moskowitz, "Rather than stockpile expensive but unproven drugs and vaccines, why not test safe, inexpensive, widely available drugs which have already shown surprising effectiveness against West Nile virus?"
About GenoMed
genomed.com
GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). To enroll in GenoMed's free clinical trial, which uses already existing, safe medication present in every drug store and hospital, just go to www.genomed.com and click on the link for the West Nile virus trial.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
http://www.genomed.com
View drug information on Relenza; Tamiflu capsule.
GenoMed a WNV Tratamentul poate funcþiona pentru Gripa aviarã - GenoMed's WNV Treatment May Work for Avian Influenza - articole medicale engleza - startsanatate